MBA

EQS-News: XTPL strengthens its presence in the USA

Retrieved on: 
星期三, 四月 10, 2024
Electronics, Sale, Business development, University, PLN, MBA, DPS, News, Delta, Urs, ICT

XTPL will deliver the Delta Printing System (DPS) device to a new client based in California in Q2 2024.

Key Points: 
  • XTPL will deliver the Delta Printing System (DPS) device to a new client based in California in Q2 2024.
  • The XTPL technology will be used in work on packaging for integrated microelectronic devices.
  • XTPL's broader activity in the USA is supported by Urs Berger, Managing Director for North America.
  • Before joining XTPL, he held key management roles at Optomec in the United States and Switzerland with a responsibility for Business Development.

Guerbet: Change in Guerbet’s Board of Directors.

Retrieved on: 
星期三, 四月 10, 2024
Financial management, Supervisory board, Trust, Central nervous system, Patient, GBT, Sanofi, Hospital, Mass meeting, Audit committee, MBA, OTC, BPI, Management

Guerbet: Change in Guerbet’s Board of Directors.

Key Points: 
  • Guerbet: Change in Guerbet’s Board of Directors.
  • Hugues Lecat’s appointment as a director will be submitted for approval at the next Shareholders’ Meeting.
  • The management experience acquired by Hugues in large companies in the pharmaceutical sector will help guide the Group in achieving further success.
  • Hugues was also a member of the Board of Directors of NOVASEP on behalf of BPI between 2012 and 2017.

EQS-News: Marco Santos to become CEO of GFT Technologies SE

Retrieved on: 
星期三, 四月 10, 2024
Deutsche Bank, Professional, Champaign–Urbana metropolitan area, Administration, STRABAG AG, Growth, USP, Computer science, CFO, Trust, MIT, Artificial intelligence, University of Cologne, Organic, Inc., GFT, University, Head, MBA, Bachelor, STEM, Tata Consultancy Services, STRABAG, International business, Singularity Group, Management

Stuttgart, 26 March 2024 – The Administrative Board of GFT Technologies SE today appointed Marco Santos as the new CEO of the digitalisation group.

Key Points: 
  • Stuttgart, 26 March 2024 – The Administrative Board of GFT Technologies SE today appointed Marco Santos as the new CEO of the digitalisation group.
  • In addition to his current role, Jochen Ruetz (56), CFO of GFT Technologies SE, will become Deputy CEO as of 1 January 2025.
  • Ulrich Dietz, Chairman of the Administrative Board of GFT Technologies, said: “Marco Santos is a guarantor of growth and innovation.
  • I am sure that GFT will continue to develop successfully with the new team.”
    Marco Santos has been appointed CEO of GFT.

InvestmentPitch Media Video Features Zero Carbon Technologies, Focussed on Recycling Technologies, Particularly for End-of-Life Battery Management

Retrieved on: 
星期五, 四月 5, 2024
Carbon, Economic Times, EV, The Economic Times, LLB, Growth, Recycling, Central Waqf Council, Shell Energy, Metal, BNP, News, Entrepreneurship, University, J.D. Power, Life, MBA, University of Cambridge, Nickel, Engineering, Chemical engineering, Fire, Renewable energy, Investment, USD, Cobalt, Mining

Vancouver, British Columbia--(Newsfile Corp. - April 5, 2024) - InvestmentPitch Media video features Zero Carbon Technologies, a company focussed on recycling technologies, particularly for end-of-life management of batteries.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - April 5, 2024) - InvestmentPitch Media video features Zero Carbon Technologies, a company focussed on recycling technologies, particularly for end-of-life management of batteries.
  • Zero Carbon has developed patented and proprietary low-CO2 battery recycling solutions that enable over 80% of the battery and 95% of valuable metals such as cobalt and nickel to be recycled.
  • For more information, please view the InvestmentPitch Media video which provides additional information about this news and the company.
  • The University of Cambridge holds 2 patents on the technology, which are used by Zero Carbon through a licensing agreement with Regenerate Technology.

AssureCare Celebrates Parth Shah's Recognition as a Leader in Healthcare Innovation

Retrieved on: 
星期二, 四月 9, 2024
Data, MBA, Biology, Biochemistry, Pharmacy, Management

CINCINNATI, April 09, 2024 (GLOBE NEWSWIRE) -- AssureCare , a leading healthcare technology company, proudly announces the recognition of Parth Shah, Vice President of Product, in HealthCare Innovation's esteemed 40 under 40 program .

Key Points: 
  • CINCINNATI, April 09, 2024 (GLOBE NEWSWIRE) -- AssureCare , a leading healthcare technology company, proudly announces the recognition of Parth Shah, Vice President of Product, in HealthCare Innovation's esteemed 40 under 40 program .
  • With over six years of experience in the healthcare sector, Parth Shah has demonstrated an unwavering commitment to revolutionizing healthcare technology.
  • Parth Shah stated, "I am deeply honored to be recognized by HealthCare Innovation for my contributions to healthcare technology.
  • This recognition is a testament to the collective efforts of the talented teams at AssureCare and our unwavering commitment to driving innovation in healthcare."

Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

Retrieved on: 
星期二, 四月 9, 2024
AbbVie, Internal medicine, Onyx Pharmaceuticals, Immunotherapy, Hematology, Science, University, Biology, MBA, University of California, Therapy, Division, Eli Lilly and Company, CMO, University of Southern California, Pharmaceutical industry

BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced the appointment of Lori Kunkel, MD, to its Board of Directors.

Key Points: 
  • BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced the appointment of Lori Kunkel, MD, to its Board of Directors.
  • Dr. Kunkel brings more than twenty-five years of experience in oncology and immunology drug development and commercialization to the Board.
  • She currently serves on the Board of Directors of Nurix Therapeutics, Inc., ORIC Pharmaceuticals, Inc., and K36 Therapeutics, Inc. She is also a scientific advisor to several clinical-stage oncology and immunotherapy companies.
  • “I am honored to transition from my role as a scientific advisor to a member of the Board of Directors,” said Dr. Kunkel.

U.S. News & World Report Ranks Georgia State’s Graduate Information Systems Program Among Nation’s 10 Best Programs and Part-time MBA in National Top 30

Retrieved on: 
星期二, 四月 9, 2024
Robinson College, Cambridge, Business, Faculty, Student, MBA, News, GMAT, GRE, AACSB, Curriculum, CIS, Business school, GPA, Management

Georgia State’s part-time MBA is 28th nationally and 17th among public university programs.

Key Points: 
  • Georgia State’s part-time MBA is 28th nationally and 17th among public university programs.
  • The university’s graduate program in computer information systems (CIS) is 10th nationally and 7th among public university programs.
  • in CIS, and embedding more experiential learning opportunities,” said Richard Phillips, dean of the Robinson College of Business.
  • Specialty rankings for graduate programs in computer information systems are based on ratings provided by business school deans and directors of AACSB-accredited MBA programs.

Global Tech Industries Group, Inc. welcomes Mr. Luke Rahbari as the Company’s new Chief Operating Officer

Retrieved on: 
星期二, 四月 9, 2024
Structured settlement, University, Growth, Toronto-Dominion Bank, Risk, Sale, Capital, MBA, RIA, Book, Investment, CBOE, Security (finance)

Mr. Rahbari began his capital markets career in 1993 as a derivatives trader and equity options specialist on the CBOE.

Key Points: 
  • Mr. Rahbari began his capital markets career in 1993 as a derivatives trader and equity options specialist on the CBOE.
  • In 2002, Mr. Rahbari was part of the management team involved in the sale of the firm to TD Bank.
  • Mr. Rahbari then ran derivatives books in New York, London, and Chicago for the bank.
  • Mr. Rahbari has extensive experience in the trading and capital markets and has been active in several private, non-public firms as well.

ABR Dynamic Funds Welcomes Fourth Partner in Firm’s History

Retrieved on: 
星期二, 四月 9, 2024
Certification, Growth, Learning, Mentorship, ABR, Partnership, Business, Knowledge, Female, MBA, CAIA, Management

"Mehar's ascent within our organization exemplifies the values of pleasant persistence and determined excellence that we hold dear at ABR," says Taylor Lukof, CEO.

Key Points: 
  • "Mehar's ascent within our organization exemplifies the values of pleasant persistence and determined excellence that we hold dear at ABR," says Taylor Lukof, CEO.
  • Shah’s elevation to partnership at ABR coincides with her recent completion of the MBA program at NYU Stern School of Business while simultaneously balancing full-time employment at ABR.
  • My journey has been shaped by a lifelong commitment to learning, both from esteemed institutions, like NYU Stern, and from mentors within ABR.
  • ABR maintains its dedication to delivering innovative investment solutions, utilizing proprietary research and quantitative models to maximize risk-adjusted returns.

Artios Pharma Bolsters Board of Directors with Appointment of Chris Liu, PhD

Retrieved on: 
星期二, 四月 9, 2024
Biotechnology, Kite, Business, Business administration, Patient, Research, DNA, Fudan University, Acquisition, NYU, MBA, Doctor of Philosophy, DDR, Master of Business Administration, Therapy, Drug development, Investment, RTW

CAMBRIDGE, United Kingdom and NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- Artios Pharma Limited (“Artios”), clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, announces the appointment of Chris Liu, Ph.D., Senior Research Analyst specializing in oncology at RTW Investments, LP (“RTW”), to its Board of Directors.

Key Points: 
  • CAMBRIDGE, United Kingdom and NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- Artios Pharma Limited (“Artios”), clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, announces the appointment of Chris Liu, Ph.D., Senior Research Analyst specializing in oncology at RTW Investments, LP (“RTW”), to its Board of Directors.
  • Niall Martin, Chief Executive Officer of Artios, said: “We are delighted to welcome Chris, a prominent research analyst to our Board of Directors.
  • Chris Liu, Ph.D. Board Director of Artios, added: “RTW is now a top shareholder of Artios following the acquisition of Arix and the expansion of our equity interest, which reflects both our confidence and excitement in Artios’ innovative platform targeting broad aspects of the DNA damage response.
  • He currently serves on the board of NiKang Therapeutics, Oricell Therapeutics and Nuance Pharma as a Board Director or Observer.